Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), pruritus (19%) and dermatitis (16%).

Serious adverse events in hepatitis C trials included neuropsychiatric disorders (homicidal ideation, suicidal ideation, suicide attempt, suicide, psychotic disorder and hallucinations), serious and severe bacterial infections (sepsis), bone marrow toxicity (cytopenia and rarely, aplastic anemia), cardiovascular disorders (hypertension, supraventricular arrhythmias and myocardial infarction), hypersensitivity (including anaphylaxis), endocrine disorders (including thyroid disorders and diabetes mellitus), autoimmune disorders (including idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, psoriasis, lupus, rheumatoid arthritis and interstitial nephritis), pulmonary disorders (dyspnea, pneumonia, bronchiolitis obliterans, interstitial pneumonitis and sarcoidosis), colitis (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reactions reported during post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal).

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that ad
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The Bio-Process Systems Alliance (BPSA) ... Single-Use Summit (ISUS 2015) will be held July ... with a primary focus on the promises and hurdles ... technical topics to business and regulatory presentations, ISUS 2015 ... of the single-use industry as the "go-to" platform in ...
(Date:5/27/2015)... Manitoba , May 27, 2015 ... customers, the Canadian International Pharmacy Association (CIPA) ... medications online from licensed Canadian pharmacies. Approximately 64% of ... maintenance medications from a non-U.S. pharmacy due to ... are not covered under their insurance plan.   ...
(Date:5/27/2015)... May 27, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today announced an upcoming poster presentation regarding its ... of Clinical Oncology (ASCO) Annual Meeting, which is being ... Chicago . "I am impressed ... in patients who have undergone treatment with aldoxorubicin across ...
Breaking Medicine Technology:BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 2BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 3Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 2Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 2CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 4CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 5
(Date:5/27/2015)... “ Nursing Homes are starting to supplant ... title of a recent April 2015 New York Times article. ... to the hospital, 20-plus years of research have documented the ... high-quality nursing homes are both safer for older patients and ... nursing homes varying widely, patients and family members may worry ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 While hair ... hair loss, a new pilot study conducted by a ... Surgery (ISHRS) has found hair follicle grafting can help ... research was partially funded by ISHRS, which offers research ... to hair restoration. , In the past decade, ...
(Date:5/27/2015)... The new http://www.carsonenergy.com includes extensive oil ... oil and gas investing, the substantial tax benefits available ... news, IRA investing, definitions and acronyms, info-graphics and educational ... experience is now in one central location, for the ... access 24 hours a day, 7 days a week. ...
(Date:5/27/2015)... NJ (PRWEB) May 27, 2015 ... Network (BCAN) , whose mission is to advance research, ... cancer, have joined forces to battle the fifth most ... in the bladder’s lining start to grow out of ... and their families at every stage of the cancer ...
(Date:5/27/2015)... May 27, 2015 Difass USA, a ... the U.S. with its first three flagship products, Dormiva™, ... purchase nationwide through http://www.difassusa.com . , A ... and productivity, but some people struggle with getting the ... is a sleep aid designed to help you fall ...
Breaking Medicine News(10 mins):Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2
... 9 Quark Pharmaceuticals, Inc., a development-stage pharmaceutical ... therapeutics, today announced that Bruce A. Molitoris, M.D., ... Indiana University , will present data demonstrating ... disease (AKI and CKD, respectively) of an animal ...
... Prevention Departments are Under-financed, Under-staffed; Patient Safety Weakened , ... are cutting staff, resources and education for infection prevention ... infections is increasing, according to a report released today ... Epidemiology (APIC). , , The "2009 ...
... Rebuild After Physical Activity , , COLUMBUS, Ohio, June 9 ... (NYSE: ABT ) today announced the EAS(R) ... on the go refuel after physical activity. The ready-to-drink sports nutrition ... , , To view the Multimedia News Release, go to: ...
... and dental expand cost-effective solutions for today,s challenging economy ... BlueCross BlueShield (Empire) today announced approval by the New ... Disability insurance as part of their broad benefit portfolio. ... Disability Insurance Company, this addition makes Empire a leading ...
... brain may help you find solutions while asleep, study suggests ... need to solve a problem, sleep on it, researchers suggest. ... University of California, San Diego, researchers say that rapid ... forming new associative networks in the brain. , "We found ...
... June 9 Par Pharmaceutical Companies, Inc. (NYSE: ... spray to the trade. Calcitonin-salmon nasal spray is a ... sales of Miacalcin were approximately $112 million in 2008, according ... Important information about calcitonin-salmon nasal spray , , ...
Cached Medicine News:Health News:Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit 2Health News:Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit 3Health News:Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit 4Health News:Hospital Infection Prevention Resources Cut, Study Says 2Health News:Hospital Infection Prevention Resources Cut, Study Says 3Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 2Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 3Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 4Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 5Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 2Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 3Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 4Health News:Got a Problem? Think About It Overnight 2Health News:Par Pharmaceutical Begins Shipment of Generic Miacalcin(R) 2
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
The Multi-Purpose Medical-Surgical Shoe...
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... use as a non-reactive quality assurance reagent in ... gondii (TOXO IgG and TOXO IgM), IgG and ... rubella IgM), IgG and IgM antibodies to cytomegalovirus ... antibodies to herpes simplex virus types 1 and ...
Medicine Products: